This site is intended for healthcare professionals
News

Arcutis initiates phase III clinical trial of topical roflumilast cream (ARQ 151) as a potential treatment for atopic dermatitis in pediatric patients between the ages of two and five years.

Read time: 2 mins
Last updated:13th Apr 2021
Published:13th Apr 2021
Condition: Atopic Dermatitis (Eczema)
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest